---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-000197"
form_type: "8-K"
ticker: "CAPR"
cik: "0001133869"
company_name: "CAPRICOR THERAPEUTICS, INC."
filed_at: "2024-01-11T23:59:59+00:00"
generated_at: "2026-06-07T00:23:23.025539+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Capricor receives $10M milestone from Nippon Shinyaku; HOPE-3 trial continues

## Summary
- Milestone payment of $10.0 million received from Nippon Shinyaku under 2022 commercialization agreement.
- Payment triggered by favorable interim futility analysis from Data Safety Monitoring Board for HOPE-3 trial.
- DSMB recommended continuation of HOPE-3 trial as planned.

## SEC filing metadata
- accession: 0001558370-24-000197
- form_type: 8-K
- ticker: CAPR
- cik: 0001133869
- company_name: CAPRICOR THERAPEUTICS, INC.
- filed_at: 2024-01-11T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1133869/000155837024000197/0001558370-24-000197-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1133869/000155837024000197/capr-20240111x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-000197
- JSON: https://secwatch.observer/filing/0001558370-24-000197.json
- Plain text: https://secwatch.observer/filing/0001558370-24-000197.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.